ArticleThe Journal of infectious diseases2026
Live-attenuated Rift Valley fever virus vaccination leads to durable, protective immunity independent of sex in C57BL/6 mice.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundRift Valley fever virus (RVFV) is a zoonotic arbovirus endemic to Africa and the Arabian Peninsula that can cause disease in humans and livestock. There are currently no licensed vaccines for human use, but several candidates are at the clinical trial stage including DDVaxTM, a preparation of live-attenuated RVFV lacking the nonstructural proteins NSs and NSm (ΔNSsΔNSm). Multiple pre-clinical studies have shown that ΔNSsΔNSm is safe and immunogenic.
methodsThe longitudinal study described in this manuscript examined the additional features of duration, sex and dose in immunogenicity and protection provided by ΔNSsΔNSm. Female and male 8-week-old C57BL/6 mice were vaccinated with either a low- or high-dose of ΔNSsΔNSm and humoral (via neutralization assay and ELISA) and cellular immunity (ELISPOT and flow cytometry) were assessed over a period of 6 months. A subset of animals were challenged with a lethal dose of wild type (WT) RVFV 6 months post-vaccination.
resultsAll vaccinated animals were protected against lethal Rift Valley fever (RVF) disease 6 months post-vaccination independent of dose or sex. Humoral immunity in the form of RVFV-specific neutralizing and binding antibodies decreased over time but remained detectable at the end of the study. RVFV-specific CD4+ T cells also decreased by 6 months post-vaccination. In contrast, virus-specific polyfunctional CD8+ T cells persisted at comparable levels throughout the study.
conclusionsThis work demonstrates that a single low-dose of ΔNSsΔNSm vaccine elicits a durable humoral and cellular immune response that persists over months and protects C57BL/6 mice against lethal RVF disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.